ABEC Launches 6000-L Single-Use Bioreactor

News
Article

The company’s Custom Single Run product line now has available bioreactors with working volumes of up to 6000 L.

ABEC, a provider of integrated solutions and services for biopharmaceutical manufacturing, announced on Sept. 10, 2019 that it now provides Custom Single Run (CSR) bioreactors with working volumes up to 6000 L.

The new 6000-L CSR bioreactor increases cell culture capacity per unit of floorspace, which is expected to save on capital spending as well as facility and disposables cost. CSR bioreactors deliver equivalent power per volume compared to stainless-steel bioreactors and can still maintain low-shear mixing, according to the company. The material, instrument, and component supply chains for the new 6000-L vessel remain fully transparent and non-proprietary, giving biopharmaceutical manufacturers better control and flexibility for managing quality, cost, and regulatory compliance.

“We understand that our customers cannot compromise on scalability and cost of goods when realizing other single-use benefits such as multi-product flexibility,” said Scott Pickering, ABEC president and CEO, in a company press release. “In applications where single-use is preferred, with [6000-L] CSR bioreactors, customers can now achieve even greater economies of scale for cell culture production.”

Source: ABEC

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content